Evolving Clinical Paradigms for LDL Lowering - Focus on Efficacy, Implications, Side Effects, and Safety Results of Clinical Trials Evaluating PCSK9 Inhibition, APOB Suppression, and Other Novel Targets for Primary and Familial Hyperlipidemia - James M. McKenney, PharmD